Back to results
US 7,030,113 B2Granted
Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
AssigneeSchering Corporation
InventorsThavalakulamgara K. Sasikumar, Duane A. Burnett
Life of this patent
Estimating the term…
Abstract
The present invention discloses compounds of formula I wherein Ar, Z, m, n, p, R1 and R8 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
Claims42
A compound represented by the structural formula
- or a pharmaceutically acceptable salt or solvate thereof, wherein
- the dashed line in
- represents either
- (i) an optional bond which may be present or absent, and if present, forms a double bond with the single bond it is adjacent to, or
- (ii) —C(R5R8)—, —C(R5R8)—C(R5R8)— or —C(R11 R12)—;
- m is 1, 2, 3 or 4;
- n is 0, 1 or 2;
- p is 0, 1 or 2;
- Ar is aryl, heteroaryl, R4-substituted aryl or R4-substituted heteroaryl;
- Z is —NR5R6, —NR5C(O)R3, —C(O)NR5R6, —NR5C(O)NR5R6, —NR5C(O)OR3, —NR5S(O2)R3, —S(O2)NR5R6, —S(O2)R3, —C(O)R3, —C(O)OR6, —OH, alkoxy,
- R1 is 1 to 4 moieties, each R1 is independently selected from the group consisting of hydrogen, —OH, halogen, alkyl, alkoxy, —OCF3, —CF3 or —CN, or two R1 moieties on adjacent carbons of the cycloalkyl ring can be joined together to form a methylenedioxy or ethylenedioxy group;
- R2 is hydrogen, alkyl, R10-substituted alkyl, cycloalkyl, R10-substituted cycloalkyl, aralkyl, heterocyclyl, —C(O)R3, —S(O2)R3 or —C(O)NR5R6;
- R3 is alkyl, aryl, aralkyl, heteroaryl, R4-substituted aralkyl, R4-substituted aryl or R4-substituted heteroaryl;
- R4 is 1 to 5 moieties, each R4 is independently selected from the consisting of hydrogen, heterocyclyl, R9-substituted heterocyclyl, heterocyclylalkyl-, R9-substituted heterocyclylalkyl, —OH, -alkoxy, —OCF3, —CN, alkyl, halogen, —NR5R6, —NR5C(O)R7, —C(O)NR5R6, —NR5S(O2)R7, —S(O2)NR5R6, —S(O2)R7, —COR7, —C(O)OR5, —CF3, -(alkylene)NR5R6, -(alkylene)NR6C(O)R7, -(alkylene)NR6S(O2)R7, -(alkylene), —NR5C(O)NR5R6, -(alkylene)NR5C(O)OR7, CHO, —C═(NOR5) and
- R5 is hydrogen or alkyl;
- R6 is hydrogen, alkyl, aryl, aralkyl or heteroaryl;
- R7 is alkyl, aryl, aralkyl or heteroaryl;
- R8 is hydrogen or alkyl;
- R9 is alkyl, —OH or hydroxyalkyl;
- R10 is alkoxy, halogen, —C(O)NR5R6, —C(O)OR6, —NR5R6 or —OH;
- R11 is hydrogen or halogen;
- and
- R12 is hydrogen or halogen.
20 more elements
A compound selected from the group consisting of
Dependencies are inferred from the claim text.